Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$13.3b

Incyte Valuation

Is INCY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INCY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INCY ($68.84) is trading below our estimate of fair value ($265.31)

Significantly Below Fair Value: INCY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INCY?

Key metric: As INCY is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INCY. This is calculated by dividing INCY's market cap by their current revenue.
What is INCY's PS Ratio?
PS Ratio3.3x
SalesUS$4.08b
Market CapUS$13.26b

Price to Sales Ratio vs Peers

How does INCY's PS Ratio compare to its peers?

The above table shows the PS ratio for INCY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.5x
BMRN BioMarin Pharmaceutical
4.5x8.2%US$12.5b
INSM Insmed
36.7x49.4%US$12.6b
EXAS Exact Sciences
4.1x9.1%US$11.0b
EXEL Exelixis
4.6x9.1%US$9.5b
INCY Incyte
3.3x8.9%US$13.3b

Price-To-Sales vs Peers: INCY is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (12.5x).

Price to Sales Ratio vs Industry

How does INCY's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.7x20.8%
INCY Incyte
 3.3x8.9%US$13.26b
BIIB Biogen
2.2x1.3%US$21.34b
MRNA Moderna
3x5.8%US$15.16b
INCY 3.3xIndustry Avg. 9.7xNo. of Companies134PS01632486480+
134 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.7x27.5%
INCY Incyte
 3.3x46.9%US$13.26b
No more companies

Price-To-Sales vs Industry: INCY is good value based on its Price-To-Sales Ratio (3.3x) compared to the US Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is INCY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INCY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio4.5x

Price-To-Sales vs Fair Ratio: INCY is good value based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (4.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INCY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$68.84
US$79.38
+15.3%
12.9%US$100.00US$52.00n/a24
Dec ’25US$74.59
US$78.31
+5.0%
12.3%US$97.00US$52.00n/a23
Nov ’25US$76.13
US$78.26
+2.8%
12.5%US$97.00US$52.00n/a23
Oct ’25US$68.06
US$74.62
+9.6%
15.5%US$92.00US$48.00n/a22
Sep ’25US$65.66
US$74.17
+13.0%
15.6%US$92.00US$48.00n/a21
Aug ’25US$64.42
US$73.94
+14.8%
15.1%US$88.00US$48.00n/a22
Jul ’25US$60.87
US$72.80
+19.6%
15.5%US$88.00US$52.00n/a22
Jun ’25US$57.79
US$72.80
+26.0%
15.5%US$88.00US$52.00n/a22
May ’25US$52.94
US$73.53
+38.9%
14.7%US$88.00US$52.00n/a21
Apr ’25US$56.64
US$76.01
+34.2%
14.1%US$92.00US$58.00n/a21
Mar ’25US$59.05
US$75.82
+28.4%
13.6%US$92.00US$58.00n/a21
Feb ’25US$59.16
US$77.05
+30.2%
15.7%US$93.00US$58.00n/a21
Jan ’25US$62.79
US$77.10
+22.8%
15.6%US$93.00US$58.00n/a21
Dec ’24US$54.02
US$76.16
+41.0%
16.5%US$93.00US$58.00US$74.5920
Nov ’24US$54.37
US$77.91
+43.3%
16.5%US$98.00US$58.00US$76.1320
Oct ’24US$57.77
US$83.59
+44.7%
13.3%US$114.00US$65.00US$68.0619
Sep ’24US$64.69
US$83.59
+29.2%
13.3%US$114.00US$65.00US$65.6619
Aug ’24US$63.69
US$83.31
+30.8%
13.4%US$114.00US$65.00US$64.4219
Jul ’24US$62.25
US$83.11
+33.5%
14.6%US$109.00US$60.00US$60.8718
Jun ’24US$61.51
US$82.42
+34.0%
14.8%US$109.00US$60.00US$57.7919
May ’24US$75.34
US$89.10
+18.3%
15.5%US$119.00US$61.00US$52.9419
Apr ’24US$72.27
US$88.67
+22.7%
15.8%US$118.00US$61.00US$56.6418
Mar ’24US$77.83
US$88.89
+14.2%
15.6%US$118.00US$63.00US$59.0518
Feb ’24US$85.60
US$89.11
+4.1%
16.2%US$120.00US$63.00US$59.1618
Jan ’24US$80.32
US$88.06
+9.6%
17.2%US$123.00US$63.00US$62.7917
Dec ’23US$80.68
US$87.94
+9.0%
17.2%US$123.00US$63.00US$54.0217

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Incyte Corporation is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Ishan MajumdarBaptista Research